Please assess the completion status of the following clinical trial:

Trial Title: Hematopoietic Stem Cell Support in Patients With Refractory Sarcoidosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18years and ≤ 60 years at the time of pretransplant evaluation.~2. Definitive diagnosis of sarcoidosis in pathologic specimen.~3. Patients who failed to respond to conventional treatment of at least 3 months duration with corticosteroids (equivalent dosage of prednisone 1.0mg/kg/day to start). Patients must also have failed two or more of the followings: TNF inhibitors (etanercept, infliximab), methotrexate, azathioprine, 6-MP, cyclosporin, tacrolimus, mycophenolate mofetil, gold, dapsone, colchicine, chloroquine/hydroxychloroquine or any other immunosuppressive or modulating drugs.~4. Failure of therapy defined by (not caused by unrelated conditions) any one of following:~   * Progressive pulmonary disease (stage II or III) defined by decline in pulmonary function (DLCo, VC or FEV1) of 15% or more over 12 months.~  * Progressive CNS disease (worsening symptoms such as paraparesis or medically refractory seizure).~  * Persistent peripheral neuropathy (one of following):~     1. Persistent muscle weakness Grade 3/5 or worse (MRC) in at least one movement (e.g. ankle dorsiflexion) in two limbs.~    2. Persistent cranial nerve involvement such as persistent facial diplegia.~    3. Persistent incapacitating sensory loss (e.g. gait ataxia, falls \> 1/month).~  * Progressive loss of vision.~  * Persistent hypercalcemia.~5. Cardiac sarcoidosis that is proven by cardiac biopsy or cardiac MRI.~Exclusion Criteria:~1. Alternative diagnosis.~2. Noncompliance to medical care.~3. \> 10 pack-year history of cigarette smoking if lung disease is the major problem.~4. Poor performance (PS) status (ECOG \>2) at the time of entry, unless decline of PS is due to the disease itself.~5. Significant end organ damage such as:~   1. Overt congestive heart failure (NYHA Class III or IV).~  2. Active ischemic heart disease, s/p myocardial infarction within 6 months, s/p unstable angina within 3 months, s/p CVA within 6 months, s/p hospitalization for CHF within 3 months.~  3. Untreated life-threatening arrhythmia.~  4. Pulmonary hypertension \> 40 mmHg.~  5. End-stage lung disease (TLC \< 55%, FVC \< 55%, or DLCO \< 40% of predicted value).~  6. Serum creatinine \> 2.5 or creatinine clearance \< 30 ml/min.~  7. Liver cirrhosis, transaminases \> 3x normal or bilirubin \> 2.0 unless due to Gilbert's disease.~6. HIV positive.~7. Uncontrolled diabetes mellitus, or any other illness that in the opinion of the investigators would jeopardize the ability of the patient to tolerate aggressive treatment.~8. Prior history of malignancy except localized basal cell or squamous skin cancer. Other malignancies for which the patient is judged to be cured by local surgical therapy, such as (but not limited to) head and neck cancer, or stage I or II breast cancer will be considered on an individual basis.~9. Positive pregnancy test, inability or unable to pursue effective means of birth control, failure to willingly accept or comprehend irreversible sterility as a side effect of therapy.~10. Significant psychological issues, social issues, psychiatric illness or mental deficiency making compliance with treatment or informed consent impossible.~11. Inability to give informed consent.~12. Major hematological abnormalities such as platelet count less than 100,000/ul, ANC less than 1000/ul.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Autologous hematopoietic stem cell transplantation (Type: EXPERIMENTAL): Autologous stem cells will be injected after conditioning
- Allogeneic stem cell transplantation (Type: EXPERIMENTAL): Allogeneic stem cells will be injected after conditioning

Based on this trial design, predict the completion outcome and termination type (if applicable).